Science Corporation’s Acquisition of Pixium Vision’s Prima Implant Technology: A Turning Point in BCI and Vision Restoration

Recently, Science Corporation announced the acquisition of the IP and related assets of Pixium Vision’s Prima implant technology. The Prima System is a photovoltaic substitute for photoreceptors that provides simultaneous use of central prosthetic and peripheral natural vision, offering a potential solution for individuals suffering from blindness. The device was specifically designed for patients with atrophic dry age-related macular degeneration (AMD), featuring a miniaturized, wireless subretinal implant paired with a pocket computer and glasses.

The acquisition has sparked excitement among industry leaders, particularly Neuralink co-founder Max Hodak, who founded Science Corporation. He expressed his enthusiasm about the opportunity to develop brain-computer interface (BCI) technology for vision restoration using the acquired technology. The deal also ensures continuity for patients enrolled in Pixium Vision’s clinical trials, as Science is now able to provide a future for the program and further advance innovative products using different modalities.

Outgoing Pixium CEO Lloyd Diamond expressed confidence in Science’s ability to continue the development and commercialization of the Prima System, stating that it now has a home with a team dedicated to helping patients. The acquisition adds to Science’s already impressive IP portfolio and represents a significant step forward in the company’s mission to develop cutting-edge BCI technology.

The deal was finalized after Pixium went into liquidation, and while terms were not disclosed, both companies are looking forward to the potential impact of this collaboration on the field of vision restoration and the lives of individuals affected by blindness.